Recent progress in targeting cancer

doi:10.18632/aging.100421

Review

. 2011 Dec;3(12):1154-62.

doi: 10.18632/aging.100421.

Recent progress in targeting cancer

Zoya N Demidenko¹, James A McCubrey

Affiliations

PMID: 22228887
PMCID: PMC3273895
DOI: 10.18632/aging.100421

Review

Recent progress in targeting cancer

Zoya N Demidenko et al. Aging (Albany NY). 2011 Dec.

. 2011 Dec;3(12):1154-62.

doi: 10.18632/aging.100421.

Authors

Zoya N Demidenko¹, James A McCubrey

Affiliation

¹ Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. zoya.demidenko@roswellpark.org

PMID: 22228887
PMCID: PMC3273895
DOI: 10.18632/aging.100421

Abstract

In recent years, numerous new targets have been identified and new experimental therapeutics have been developed. Importantly, existing non-cancer drugs found novel use in cancer therapy. And even more importantly, new original therapeutic strategies to increase potency, selectivity and decrease detrimental side effects have been evaluated. Here we review some recent advances in targeting cancer.

PubMed Disclaimer

Conflict of interest statement

The authors of this manuscript have no conflict of interest to declare.

Cited by

Profiling of Human Molecular Pathways Affected by Retrotransposons at the Level of Regulation by Transcription Factor Proteins.
Nikitin D, Penzar D, Garazha A, Sorokin M, Tkachev V, Borisov N, Poltorak A, Prassolov V, Buzdin AA. Nikitin D, et al. Front Immunol. 2018 Jan 30;9:30. doi: 10.3389/fimmu.2018.00030. eCollection 2018. Front Immunol. 2018. PMID: 29441061 Free PMC article.
NRF2 and p53: Januses in cancer?
Rotblat B, Melino G, Knight RA. Rotblat B, et al. Oncotarget. 2012 Nov;3(11):1272-83. doi: 10.18632/oncotarget.754. Oncotarget. 2012. PMID: 23174755 Free PMC article. Review.
p63 the guardian of human reproduction.
Amelio I, Grespi F, Annicchiarico-Petruzzelli M, Melino G. Amelio I, et al. Cell Cycle. 2012 Dec 15;11(24):4545-51. doi: 10.4161/cc.22819. Epub 2012 Nov 19. Cell Cycle. 2012. PMID: 23165243 Free PMC article. Review.
Persistent DNA damage caused by low levels of mitomycin C induces irreversible cell senescence.
McKenna E, Traganos F, Zhao H, Darzynkiewicz Z. McKenna E, et al. Cell Cycle. 2012 Aug 15;11(16):3132-40. doi: 10.4161/cc.21506. Epub 2012 Aug 8. Cell Cycle. 2012. PMID: 22871735 Free PMC article.
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon.
Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A, Montalto G. Cervello M, et al. Oncotarget. 2012 Mar;3(3):236-60. doi: 10.18632/oncotarget.466. Oncotarget. 2012. PMID: 22470194 Free PMC article. Review.

See all "Cited by" articles

References

1. Redding TW, Schally AV. Inhibition of cell growth by a hypothalamic peptide. Proc Natl Acad Sci U S A. 1982;79:7014–7018. - PMC - PubMed
1. Barabutis N, Schally AV. Growth hormone-releasing hormone: extrapituitary effects in physiology and pathology. Cell Cycle. 2010;9:4110–4116. - PubMed
1. Schally AV, Varga JL, Engel JB. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab. 2008;4:33–43. - PubMed
1. Hohla F, Schally AV. Targeting gastrin releasing peptide receptors: New options for the therapy and diagnosis of cancer. Cell Cycle. 2010;9:1738–1741. - PubMed
1. Siejka A, Barabutis N, Schally AV. GHRH antagonist MZ-5-156 increases the expression of AMPK in A549 lung cancer cells. Cell Cycle. 2011;10:3714–3718. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources

[1] Redding TW, Schally AV. Inhibition of cell growth by a hypothalamic peptide. Proc Natl Acad Sci U S A. 1982;79:7014–7018. - PMC - PubMed

[2] Redding TW, Schally AV. Inhibition of cell growth by a hypothalamic peptide. Proc Natl Acad Sci U S A. 1982;79:7014–7018. - PMC - PubMed

[3] Barabutis N, Schally AV. Growth hormone-releasing hormone: extrapituitary effects in physiology and pathology. Cell Cycle. 2010;9:4110–4116. - PubMed

[4] Barabutis N, Schally AV. Growth hormone-releasing hormone: extrapituitary effects in physiology and pathology. Cell Cycle. 2010;9:4110–4116. - PubMed

[5] Schally AV, Varga JL, Engel JB. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab. 2008;4:33–43. - PubMed

[6] Schally AV, Varga JL, Engel JB. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab. 2008;4:33–43. - PubMed

[7] Hohla F, Schally AV. Targeting gastrin releasing peptide receptors: New options for the therapy and diagnosis of cancer. Cell Cycle. 2010;9:1738–1741. - PubMed

[8] Hohla F, Schally AV. Targeting gastrin releasing peptide receptors: New options for the therapy and diagnosis of cancer. Cell Cycle. 2010;9:1738–1741. - PubMed

[9] Siejka A, Barabutis N, Schally AV. GHRH antagonist MZ-5-156 increases the expression of AMPK in A549 lung cancer cells. Cell Cycle. 2011;10:3714–3718. - PubMed

[10] Siejka A, Barabutis N, Schally AV. GHRH antagonist MZ-5-156 increases the expression of AMPK in A549 lung cancer cells. Cell Cycle. 2011;10:3714–3718. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Recent progress in targeting cancer

Affiliation

Recent progress in targeting cancer

Authors

Affiliation

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources